TN2011000216A1 - Anti-cmet antibody - Google Patents

Anti-cmet antibody

Info

Publication number: TN2011000216A1
Authority: TN; Tunisia
Prior art keywords: antibody; receptor; met; cmet antibody; specifically
Prior art date: 2008-12-02

Application number

TN2011000216A

Other languages

English (en)

Inventor

Thierry Wurch

Cedric Bes

Liliane Goetsch

Original Assignee

Pf Medicament

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-02

Filing date

2011-05-03

Publication date

2012-12-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41693124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000216(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-12-02 Priority claimed from PCT/IB2008/055663 external-priority patent/WO2010064089A1/fr

2011-05-03 Application filed by Pf Medicament filed Critical Pf Medicament

2012-12-17 Publication of TN2011000216A1 publication Critical patent/TN2011000216A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)
Connection Of Motors, Electrical Generators, Mechanical Devices, And The Like (AREA)

TN2011000216A 2008-12-02 2011-05-03 Anti-cmet antibody TN2011000216A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/IB2008/055663 WO2010064089A1 (fr)	2008-12-02	2008-12-02	Nouvel anticorps anti-cmet
US18450209P	2009-06-05	2009-06-05
PCT/EP2009/066201 WO2010069765A1 (fr)	2008-12-02	2009-12-02	Anticorps anti-cmet

Publications (1)

Publication Number	Publication Date
TN2011000216A1 true TN2011000216A1 (en)	2012-12-17

Family

ID=41693124

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2011000216A TN2011000216A1 (en)	2008-12-02	2011-05-03	Anti-cmet antibody

Country Status (38)

Country	Link
US (4)	US8741290B2 (fr)
EP (4)	EP3135691B1 (fr)
JP (3)	JP5863458B2 (fr)
KR (1)	KR101838299B1 (fr)
CN (2)	CN103351438B (fr)
AR (1)	AR074439A1 (fr)
AU (3)	AU2009328318C1 (fr)
BR (2)	BR122019023930B1 (fr)
CA (1)	CA2743433C (fr)
CL (2)	CL2011001296A1 (fr)
CO (1)	CO6382139A2 (fr)
CR (1)	CR20110324A (fr)
CY (2)	CY1119172T1 (fr)
DK (2)	DK2370468T3 (fr)
EC (1)	ECSP11011127A (fr)
ES (3)	ES2827277T3 (fr)
GE (2)	GEP20135930B (fr)
HR (2)	HRP20171011T8 (fr)
HU (3)	HUE051288T2 (fr)
IL (2)	IL213273A0 (fr)
LT (2)	LT3135691T (fr)
MA (1)	MA32892B1 (fr)
MX (2)	MX2011005677A (fr)
MY (2)	MY192567A (fr)
NZ (1)	NZ593853A (fr)
PE (1)	PE20120343A1 (fr)
PH (1)	PH12015501515A1 (fr)
PL (3)	PL2370468T3 (fr)
PT (3)	PT3135691T (fr)
RS (2)	RS56204B1 (fr)
RU (2)	RU2015127471A (fr)
SA (2)	SA109300720B1 (fr)
SG (2)	SG171851A1 (fr)
SI (3)	SI3135691T1 (fr)
TN (1)	TN2011000216A1 (fr)
TW (2)	TWI523866B (fr)
WO (1)	WO2010069765A1 (fr)
ZA (1)	ZA201105164B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2014681A1 (fr)	2007-07-12	2009-01-14	Pierre Fabre Medicament	Nouveaux anticorps à inhibition de dimérisation c-met, et utilisations correspondantes
US8545839B2 (en) *	2008-12-02	2013-10-01	Pierre Fabre Medicament	Anti-c-Met antibody
EP2287197A1 (fr) *	2009-08-21	2011-02-23	Pierre Fabre Medicament	Anticorps anti-cMET et son utilisation pour la détection et le diagnostic du cancer
JP6055312B2 (ja)	2010-03-10	2017-01-11	ゲンマブエー／エス	Ｃ−ｍｅｔに対するモノクローナル抗体
SG188324A1 (en)	2010-09-03	2013-04-30	Academia Sinica	Anti-c-met antibody and methods of use thereof
US8637027B2 (en)	2010-11-03	2014-01-28	Argen-X B.V.	Anti c-Met antibodies
JP6400470B2 (ja)	2011-05-16	2018-10-03	ジェネロン（シャンハイ）コーポレイションリミテッド	多重特異性Ｆａｂ融合タンパク質および使用法
KR20130036993A (ko) *	2011-10-05	2013-04-15	삼성전자주식회사	ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
KR101865223B1 (ko)	2011-10-05	2018-06-08	삼성전자주식회사	항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
WO2013064700A2 (fr)	2011-11-03	2013-05-10	Argen-X B.V.	Polypeptides chimériques et leurs procédés d'utilisation
KR101463098B1 (ko) *	2011-11-28	2014-11-27	한국생명공학연구원	ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
US8900582B2 (en)	2011-12-22	2014-12-02	Samsung Electronics Co., Ltd.	Deimmunized anti c-Met humanized antibodies and uses thereof
JP6429771B2 (ja) *	2012-06-21	2018-11-28	ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	ｃ−Ｍｅｔに結合する抗原結合タンパク質
US9931400B2 (en)	2012-09-12	2018-04-03	Samsung Electronics Co., Ltd.	Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
EP2839860B1 (fr)	2012-10-12	2019-05-01	MedImmune Limited	Pyrrolobenzodiazépines et ses conjugués
JP6444902B2 (ja)	2013-03-13	2018-12-26	メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅＬｉｍｉｔｅｄ	ピロロベンゾジアゼピン及びその結合体
KR102049990B1 (ko) *	2013-03-28	2019-12-03	삼성전자주식회사	c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
EP2992019B1 (fr)	2013-04-30	2019-03-06	Agency For Science, Technology And Research	Anticorps mab 2 anti-met
US9567641B2 (en) *	2013-07-03	2017-02-14	Samsung Electronics Co., Ltd.	Combination therapy for the treatment of cancer using an anti-C-met antibody
US9717715B2 (en)	2013-11-15	2017-08-01	Samsung Electronics Co., Ltd.	Method of combination therapy using an anti-C-Met antibody
EP3083697B1 (fr) *	2013-12-20	2019-04-17	Development Center for Biotechnology	Anticorps spécifiques de l'alpha-énolase et procédés d'utilisation en thérapie anticancéreuse
JP6531166B2 (ja)	2014-09-10	2019-06-12	メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅＬｉｍｉｔｅｄ	ピロロベンゾジアゼピン及びそのコンジュゲート
CN107613974B (zh) *	2015-03-16	2021-01-15	塞尔德克斯医疗公司	抗-met抗体及其使用方法
JP6669882B2 (ja)	2016-02-05	2020-03-18	ヘリックスミスカンパニーリミテッド	抗−ｃ−ＭＥＴ抗体及びその用途
AU2017233121B2 (en)	2016-03-15	2023-12-21	Itabmed (Hk) Limited	Multispecific Fab fusion proteins and use thereof
ES2864150T3 (es) *	2016-05-17	2021-10-13	Abbvie Biotherapeutics Inc	Conjugados de fármacos con anticuerpos anti-cMet y métodos para su uso
US10457726B2 (en)	2016-06-30	2019-10-29	University Of Connecticut	Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
CN109862919A (zh)	2016-10-11	2019-06-07	免疫医疗有限公司	抗体-药物缀合物联合免疫介导的治疗剂
RU2741228C2 (ru) *	2016-11-14	2021-01-22	Общество С Ограниченной Ответственностью "Панацела Лабс"	Противоопухолевые эффекты вирусного вектора, кодирующего толл-подобный рецептор и агонист толл-подобного рецептора
TWI782930B (zh)	2016-11-16	2022-11-11	美商再生元醫藥公司	抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
WO2018129029A1 (fr) *	2017-01-04	2018-07-12	Immunogen, Inc.	Anticorps anti-met, immunoconjugués et utilisations de ceux-ci
CN109771642B (zh) *	2017-11-13	2022-09-20	同济大学苏州研究院	c-MET激动型抗体及其用途
GB201803892D0 (en) *	2018-03-12	2018-04-25	Ultrahuman Six Ltd	C-met binding agents
KR20210016562A (ko)	2018-05-23	2021-02-16	에이디씨 테라퓨틱스 에스에이	분자 애쥬번트
CA3108646A1 (fr) *	2018-08-08	2020-02-13	Dragonfly Therapeutics, Inc.	Proteines de liaison a nkg2d, a cd16 et a un antigene associe a une tumeur
EP3847196A4 (fr)	2018-09-07	2023-01-04	ITabMed (HK) Limited	Protéines de liaison à un antigène bispécifiques et leurs utilisations
CN109541221B (zh) *	2018-10-24	2022-03-22	益善生物技术股份有限公司	一种c-Met特异性抗体、组合物及试剂盒
KR102353568B1 (ko) *	2018-11-14	2022-01-20	주식회사 헬릭스미스	안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
CN113874392B (zh) *	2019-03-28	2025-10-21	丹尼斯科美国公司	工程化抗体
US11896682B2 (en)	2019-09-16	2024-02-13	Regeneron Pharmaceuticals, Inc.	Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
US20230372528A1 (en)	2020-10-16	2023-11-23	University Of Georgia Research Foundation, Inc.	Glycoconjugates
GB202102396D0 (en)	2021-02-19	2021-04-07	Adc Therapeutics Sa	Molecular adjuvant
MX2023011733A (es)	2021-04-06	2023-10-13	Abbvie Biotherapeutics Inc	Metodos para el tratamiento del carcinoma de pulmon de celulas no peque?as usando telisotuzumab vedotin.
AU2022254291A1 (en) *	2021-04-08	2023-10-12	Byondis B.V.	Anti-c-met antibodies and antibody-drug conjugates
TWI895608B (zh) *	2021-04-29	2025-09-01	愛爾蘭商艾伯維製造管理無限公司	抗c-Met抗體藥物結合物
JP2024541058A (ja)	2021-11-03	2024-11-06	ハンジョウディーエーシーバイオテックシーオー．，エルティディ．	抗体の特異的共役
US20230285394A1 (en)	2022-03-11	2023-09-14	Abbvie Biotherapeutics Inc.	Methods of treatment of non-small-cell lung carcinoma using telisotuzummab vedotin and osimertinib
WO2024243450A1 (fr)	2023-05-23	2024-11-28	Abbvie Inc.	Méthodes de traitement utilisant des conjugués anticorps-médicament anti-c-met
WO2025149667A1 (fr)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Conjugués anticorps-médicament et leurs utilisations

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4424200A (en)	1979-05-14	1984-01-03	Nuc Med Inc.	Method for radiolabeling proteins with technetium-99m
US4479930A (en)	1982-07-26	1984-10-30	Trustees Of The University Of Massachusetts	Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4831175A (en)	1986-09-05	1989-05-16	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8924581D0 (en)	1989-11-01	1989-12-20	Pa Consulting Services	Bleaching of hair
GB9014932D0 (en)	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
WO1994004679A1 (fr) *	1991-06-14	1994-03-03	Genentech, Inc.	Procede pour fabriquer des anticorps humanises
JPH05244982A (ja)	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	擬人化ｂ−ｂ１０
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US5686292A (en) *	1995-06-02	1997-11-11	Genentech, Inc.	Hepatocyte growth factor receptor antagonist antibodies and uses thereof
WO2002055106A2 (fr) *	2001-01-09	2002-07-18	Merck Patent Gmbh	Polytherapie faisant appel a des inhibiteurs de recepteurs tyrosine kinase et a des inhibiteurs d'angiogenese
WO2004072117A2 (fr) *	2003-02-13	2004-08-26	Pharmacia Corporation	Anticorps contre c-met dans le traitement de cancers
HN2004000285A (es)	2003-08-04	2006-04-27	Pfizer Prod Inc	ANTICUERPOS DIRIGIDOS A c-MET
WO2005058965A1 (fr)	2003-12-11	2005-06-30	Genentech, Inc.	Methodes et compositions pour inhiber une dimerisation et une activation de c-met
PT1773885E (pt) *	2004-08-05	2010-07-21	Genentech Inc	Antagonistas anti-cmet humanizados
WO2006116260A2 (fr) *	2005-04-26	2006-11-02	Medimmune, Inc.	Modulation de la fonction d'effecteur d'anticorps par ingenierie de domaine 'charniere'
CA2854576A1 (fr) *	2005-07-18	2007-01-25	Haichun Huang	Anticorps neutralisants anti-b7rp1 humains
US8652469B2 (en)	2005-07-28	2014-02-18	Novartis Ag	M-CSF-specific monoclonal antibody and uses thereof
JP5536445B2 (ja) *	2006-03-30	2014-07-02	ノバルティスアーゲー	ｃ−Ｍｅｔの抗体の組成物およびその使用方法
EP2014681A1 (fr) *	2007-07-12	2009-01-14	Pierre Fabre Medicament	Nouveaux anticorps à inhibition de dimérisation c-met, et utilisations correspondantes
US8545839B2 (en)	2008-12-02	2013-10-01	Pierre Fabre Medicament	Anti-c-Met antibody

2009
- 2009-12-01 AR ARP090104624A patent/AR074439A1/es active IP Right Grant
- 2009-12-02 SI SI200931893T patent/SI3135691T1/sl unknown
- 2009-12-02 HU HUE18188726A patent/HUE051288T2/hu unknown
- 2009-12-02 BR BR122019023930-4A patent/BR122019023930B1/pt active IP Right Grant
- 2009-12-02 US US13/132,211 patent/US8741290B2/en active Active
- 2009-12-02 CN CN201310286587.2A patent/CN103351438B/zh active Active
- 2009-12-02 PT PT16192250T patent/PT3135691T/pt unknown
- 2009-12-02 SI SI200931680T patent/SI2370468T1/sl unknown
- 2009-12-02 CA CA2743433A patent/CA2743433C/fr active Active
- 2009-12-02 RU RU2015127471A patent/RU2015127471A/ru not_active Application Discontinuation
- 2009-12-02 EP EP16192250.5A patent/EP3135691B1/fr active Active
- 2009-12-02 PL PL09771324T patent/PL2370468T3/pl unknown
- 2009-12-02 DK DK09771324.2T patent/DK2370468T3/en active
- 2009-12-02 RS RS20170671A patent/RS56204B1/sr unknown
- 2009-12-02 RU RU2011124751/10A patent/RU2560257C2/ru active
- 2009-12-02 PT PT181887266T patent/PT3431502T/pt unknown
- 2009-12-02 SG SG2011038817A patent/SG171851A1/en unknown
- 2009-12-02 EP EP18188726.6A patent/EP3431502B1/fr active Active
- 2009-12-02 MX MX2011005677A patent/MX2011005677A/es active IP Right Grant
- 2009-12-02 WO PCT/EP2009/066201 patent/WO2010069765A1/fr not_active Ceased
- 2009-12-02 RS RS20181344A patent/RS58018B1/sr unknown
- 2009-12-02 EP EP20187010.2A patent/EP3757132A1/fr active Pending
- 2009-12-02 GE GEAP200912279A patent/GEP20135930B/en unknown
- 2009-12-02 SG SG2013005772A patent/SG187518A1/en unknown
- 2009-12-02 PL PL18188726T patent/PL3431502T3/pl unknown
- 2009-12-02 TW TW103130374A patent/TWI523866B/zh active
- 2009-12-02 MY MYPI2020006937A patent/MY192567A/en unknown
- 2009-12-02 GE GEAP200912919A patent/GEP20146207B/en unknown
- 2009-12-02 SI SI200932092T patent/SI3431502T1/sl unknown
- 2009-12-02 PL PL16192250T patent/PL3135691T3/pl unknown
- 2009-12-02 MY MYPI2011002426A patent/MY185200A/en unknown
- 2009-12-02 BR BRPI0923231A patent/BRPI0923231B8/pt active IP Right Grant
- 2009-12-02 TW TW098141151A patent/TWI459964B/zh active
- 2009-12-02 LT LTEP16192250.5T patent/LT3135691T/lt unknown
- 2009-12-02 HU HUE16192250A patent/HUE040553T2/hu unknown
- 2009-12-02 DK DK16192250.5T patent/DK3135691T3/en active
- 2009-12-02 CN CN200980148150.4A patent/CN102227446B/zh active Active
- 2009-12-02 PT PT97713242T patent/PT2370468T/pt unknown
- 2009-12-02 LT LTEP09771324.2T patent/LT2370468T/lt unknown
- 2009-12-02 JP JP2011539008A patent/JP5863458B2/ja active Active
- 2009-12-02 ES ES18188726T patent/ES2827277T3/es active Active
- 2009-12-02 AU AU2009328318A patent/AU2009328318C1/en active Active
- 2009-12-02 EP EP09771324.2A patent/EP2370468B1/fr active Active
- 2009-12-02 ES ES16192250T patent/ES2697098T3/es active Active
- 2009-12-02 NZ NZ593853A patent/NZ593853A/xx unknown
- 2009-12-02 HR HRP20171011TT patent/HRP20171011T8/hr unknown
- 2009-12-02 KR KR1020117013758A patent/KR101838299B1/ko active Active
- 2009-12-02 HU HUE09771324A patent/HUE035047T2/en unknown
- 2009-12-02 ES ES09771324.2T patent/ES2629855T3/es active Active
- 2009-12-02 PE PE2011001117A patent/PE20120343A1/es active IP Right Grant
- 2009-12-05 SA SA109300720A patent/SA109300720B1/ar unknown
- 2009-12-05 SA SA112331005A patent/SA112331005B1/ar unknown
2011
- 2011-05-03 TN TN2011000216A patent/TN2011000216A1/fr unknown
- 2011-05-30 MX MX2015000383A patent/MX341014B/es unknown
- 2011-05-31 IL IL213273A patent/IL213273A0/en active IP Right Grant
- 2011-06-01 CL CL2011001296A patent/CL2011001296A1/es unknown
- 2011-06-10 MA MA33933A patent/MA32892B1/fr unknown
- 2011-06-13 EC EC2011011127A patent/ECSP11011127A/es unknown
- 2011-06-13 CR CR20110324A patent/CR20110324A/es unknown
- 2011-06-14 CO CO11073992A patent/CO6382139A2/es active IP Right Grant
- 2011-07-13 ZA ZA2011/05164A patent/ZA201105164B/en unknown
2012
- 2012-09-14 US US13/619,730 patent/US8747850B2/en active Active
- 2012-09-14 US US13/619,920 patent/US8765128B2/en active Active
- 2012-09-14 US US13/619,910 patent/US8729249B2/en active Active
2014
- 2014-01-24 CL CL2014000181A patent/CL2014000181A1/es unknown
- 2014-03-13 IL IL231525A patent/IL231525B/en active IP Right Grant
2015
- 2015-07-03 PH PH12015501515A patent/PH12015501515A1/en unknown
- 2015-12-15 JP JP2015244007A patent/JP6074018B2/ja active Active
2016
- 2016-02-04 AU AU2016200725A patent/AU2016200725C1/en active Active
2017
- 2017-01-05 JP JP2017000641A patent/JP6309657B2/ja active Active
- 2017-06-09 AU AU2017203929A patent/AU2017203929B2/en active Active
- 2017-07-03 CY CY20171100707T patent/CY1119172T1/el unknown
2018
- 2018-11-09 CY CY181101191T patent/CY1121025T1/el unknown
- 2018-11-09 HR HRP20181868TT patent/HRP20181868T1/hr unknown

Also Published As

Publication number	Publication date
MY192567A (en)	2022-08-29
AU2009328318B2 (en)	2015-11-05
SI3135691T1 (sl)	2018-12-31
SA109300720B1 (ar)	2013-05-25
SG187518A1 (en)	2013-02-28
HRP20171011T1 (hr)	2017-09-22
GEP20135930B (en)	2013-10-10
MY185200A (en)	2021-04-30
JP2012510280A (ja)	2012-05-10
BRPI0923231A2 (pt)	2016-01-26
JP5863458B2 (ja)	2016-02-16
AU2017203929A1 (en)	2017-07-06
DK2370468T3 (en)	2017-06-19
JP2016117721A (ja)	2016-06-30
CO6382139A2 (es)	2012-02-15
US20130109844A1 (en)	2013-05-02
ECSP11011127A (es)	2011-07-29
CA2743433A1 (fr)	2010-06-24
CR20110324A (es)	2011-07-28
SI2370468T1 (sl)	2017-08-31
HK1162536A1 (zh)	2012-08-31
AU2016200725B2 (en)	2017-05-25
CA2743433C (fr)	2019-06-11
EP3431502A1 (fr)	2019-01-23
RS56204B1 (sr)	2017-11-30
TWI459964B (zh)	2014-11-11
KR101838299B1 (ko)	2018-03-14
PL3135691T3 (pl)	2019-02-28
SG171851A1 (en)	2011-07-28
CL2011001296A1 (es)	2011-08-26
HUE051288T2 (hu)	2021-03-01
NZ593853A (en)	2013-03-28
US8747850B2 (en)	2014-06-10
MX341014B (es)	2016-08-03
IL231525A0 (en)	2014-04-30
HUE040553T2 (hu)	2019-03-28
HUE035047T2 (en)	2018-05-02
AU2017203929B2 (en)	2019-03-28
IL231525B (en)	2019-07-31
AU2009328318C1 (en)	2017-11-02
JP6309657B2 (ja)	2018-04-11
CY1119172T1 (el)	2018-02-14
GEP20146207B (en)	2014-12-10
US8729249B2 (en)	2014-05-20
KR20110097839A (ko)	2011-08-31
PT2370468T (pt)	2017-07-13
WO2010069765A1 (fr)	2010-06-24
ES2827277T3 (es)	2021-05-20
LT2370468T (lt)	2017-07-10
EP2370468A1 (fr)	2011-10-05
HRP20181868T1 (hr)	2019-01-11
US20130109840A1 (en)	2013-05-02
PT3135691T (pt)	2018-11-27
JP6074018B2 (ja)	2017-02-01
US20110239316A1 (en)	2011-09-29
PE20120343A1 (es)	2012-04-16
US8741290B2 (en)	2014-06-03
DK3135691T3 (en)	2018-11-19
TW201446805A (zh)	2014-12-16
ES2629855T3 (es)	2017-08-16
CY1121025T1 (el)	2019-12-11
ES2697098T3 (es)	2019-01-22
JP2017099392A (ja)	2017-06-08
LT3135691T (lt)	2018-11-12
AU2016200725C1 (en)	2017-10-19
AR074439A1 (es)	2011-01-19
SI3431502T1 (sl)	2021-01-29
MX2011005677A (es)	2011-06-30
US8765128B2 (en)	2014-07-01
PH12015501515A1 (en)	2015-12-14
EP3135691A1 (fr)	2017-03-01
HK1190414A1 (zh)	2014-07-04
HRP20171011T8 (hr)	2019-01-25
IL213273A0 (en)	2011-07-31
RU2015127471A (ru)	2018-12-21
RU2011124751A (ru)	2013-01-10
RS58018B1 (sr)	2019-02-28
CL2014000181A1 (es)	2014-07-25
BR122019023930B1 (pt)	2021-05-04
CN102227446A (zh)	2011-10-26
SA112331005B1 (ar)	2015-09-13
EP2370468B1 (fr)	2017-04-05
EP3135691B1 (fr)	2018-08-15
PL3431502T3 (pl)	2020-12-28
CN103351438B (zh)	2016-04-20
ZA201105164B (en)	2012-03-28
AU2016200725A1 (en)	2016-02-25
TW201023892A (en)	2010-07-01
BRPI0923231B8 (pt)	2021-05-25
CN103351438A (zh)	2013-10-16
EP3757132A1 (fr)	2020-12-30
CN102227446B (zh)	2015-10-21
US20130109841A1 (en)	2013-05-02
AU2009328318A1 (en)	2011-07-28
TWI523866B (zh)	2016-03-01
PT3431502T (pt)	2020-10-29
BRPI0923231B1 (pt)	2020-04-28
PL2370468T3 (pl)	2017-09-29
EP3431502B1 (fr)	2020-07-22
RU2560257C2 (ru)	2015-08-20
MA32892B1 (fr)	2011-12-01

Publication	Publication Date	Title
PH12015501515A1 (en)	2015-12-14	Anti-cmet antibody
MY150136A (en)	2013-11-29	Picolinamide derivatives as kinase inhibitors
MX2009009304A (es)	2009-11-18	Inhibidores de cinasa pim y metodos para su uso.
TW201129378A (en)	2011-09-01	Materials and methods for treating or preventing HER-3 associated diseases
WO2012059857A3 (fr)	2012-07-19	Composition d'antcorps pan-her
MX2007015487A (es)	2008-04-09	Moleculas que son capaces de inhibir la union entre el factor de crecimiento de nervios y el receptor trka como analgesicos con efecto prolongado.
MX2010010317A (es)	2010-10-04	Compuestos heterociclicos novedosos y usos de los mismos.
WO2012032209A3 (fr)	2012-07-12	Composition pharmaceutique pour le traitement de l'oeil sec
UA109878C2 (uk)	2015-10-26	Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
MY163096A (en)	2017-08-15	Novel anti-cmet antibody
CL2009000873A1 (es)	2009-09-11	Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b
MX2010005031A (es)	2010-06-25	Anticuerpos de axl.
EA200870410A1 (ru)	2009-12-30	Антагонисты киназы
CL2008002097A1 (es)	2009-02-20	Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
WO2009020933A3 (fr)	2009-03-26	Utilisation thérapeutique anticorps de récepteur anti-tweak
CL2008001025A1 (es)	2008-10-17	Compuestos derivados de pirimido[5,4-d]pirimidina-2,4,6,8-tetraona; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastorno metabolico, dislipidemia y cancer.
MX2011000255A (es)	2014-04-16	Combinacion de un antagonista a c-met y un compuesto aminoheteroarilo, para el tratamiento de cancer.
MX2010009743A (es)	2010-09-28	Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami
WO2012001065A3 (fr)	2012-03-29	Méthode de prévention ou de traitement des tumeurs cutanées
MX2014009277A (es)	2015-03-03	Antagonistas alk1 y sus usos en el tratamiento de carcinoma de celula renal.
MX2009003039A (es)	2009-04-02	Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer.
MX2010008994A (es)	2010-09-07	Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario.
MX2011008878A (es)	2011-09-21	Usos de antagonistas de los receptores de nk.
MX2012013527A (es)	2013-04-08	Quinazolinas policíclicas, preparación de las mismas, y uso de las mismas.
UA98472C2 (ru)	2012-05-25	Применение агониста рецептора epo человека для лечения интолерантности к глюкозе